Novavax Cuts 2024 Revenue Forecast
This is a news story, published by Yahoo Finance, that relates primarily to COVID news.
drug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Novavax. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest COVID vaccine news, vaccine maker news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
COVID vaccinesReuters
•Novavax cuts 2024 revenue forecast on lower COVID vaccine sales
81% Informative
Shares of the company were down 14% in premarket trading.
The vaccine maker now expects $275 million to $375 million in product sales for the year .
Novavax has struggled to sell its protein-based COVID vaccines and failed to make a significant dent in the market share of key players.
VR Score
92
Informative language
98
Neutral language
81
Article tone
semi-formal
Language
English
Language complexity
47
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links